Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGY0UT)

Drug Name
Estrogen Drug Info
Cross-matching ID
PubChem CID
5757
TTD Drug ID
D0M8PD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 2.27 0.00e+0 52/108 (48.15%) NVL;RPP40;NXT1;...
Spliceosome 1.87 2.26e-2 101/150 (67.33%) HSPA8;TRA2B;HNRNPM;...
DNA replication 1.82 1.88e-2 34/36 (94.44%) PCNA;FEN1;POLE2;...
Oocyte meiosis 1.81 1.98e-2 90/129 (69.77%) CDC20;PLK1;CCNB1;...
RNA transport 1.77 2.37e-2 128/186 (68.82%) NUP50;NUP85;RPP40;...
Cell cycle 1.77 1.98e-2 110/124 (88.71%) CDC20;PCNA;PLK1;...
mRNA surveillance pathway 1.75 1.78e-2 71/98 (72.45%) NXT1;NXF1;PPP2R5A;...
Progesterone-mediated oocyte maturation 1.74 1.69e-2 75/100 (75%) PLK1;CCNB1;STK10;...
Fanconi anemia pathway 1.65 4.39e-2 36/54 (66.67%) USP1;BLM;FANCG;...
Primary bile acid biosynthesis -1.60 4.49e-2 15/17 (88.24%) SCP2;BAAT;CYP46A1;...
Amoebiasis -1.63 4.15e-2 99/102 (97.06%) IL1R2;CD1A;LAMA3;...
Phenylalanine metabolism -1.63 3.85e-2 14/17 (82.35%) AOC3;ALDH3B1;MAOA;...
Galactose metabolism -1.63 3.94e-2 26/31 (83.87%) GAA;AKR1B1;PFKM;...
Osteoclast differentiation -1.64 3.78e-2 117/127 (92.13%) LILRA1;FCGR2A;JAK1;...
Intestinal immune network for IgA production -1.65 3.54e-2 38/48 (79.17%) HLA-DQB1;CXCR4;TNFRSF13B;...
Other glycan degradation -1.65 3.46e-2 13/18 (72.22%) MANBA;MAN2B1;ENGASE;...
Necroptosis -1.66 3.13e-2 113/159 (71.07%) CAMK2G;CHMP2A;FTL;...
Type I diabetes mellitus -1.67 2.83e-2 38/43 (88.37%) FASLG;HLA-DOA;LTA;...
Phagosome -1.67 2.83e-2 118/152 (77.63%) HLA-E;ATP6V1B2;ATP6V0E2;...
Basal cell carcinoma -1.69 2.70e-2 41/63 (65.08%) DVL1;TCF7L1;GLI1;...
Pentose phosphate pathway -1.69 2.76e-2 25/30 (83.33%) PGM1;RGN;RBKS;...
ECM-receptor interaction -1.70 2.76e-2 80/88 (90.91%) LAMA3;LAMC2;THBS3;...
Inflammatory bowel disease -1.72 2.44e-2 58/65 (89.23%) IFNGR1;IL6;TLR2;...
Leishmaniasis -1.74 1.73e-2 67/77 (87.01%) FCGR2A;JAK1;IFNGR1;...
Arachidonic acid metabolism -1.75 1.66e-2 48/61 (78.69%) PLA2G4A;GPX7;ALOX15B;...
Adherens junction -1.75 1.68e-2 63/71 (88.73%) CSNK2A1;PTPRJ;EGFR;...
Notch signaling pathway -1.76 1.81e-2 49/59 (83.05%) RBPJ;ADAM17;DVL2;...
Staphylococcus aureus infection -1.77 1.38e-2 72/95 (75.79%) FCGR2A;FPR3;FPR2;...
Hematopoietic cell lineage -1.78 1.26e-2 90/99 (90.91%) KIT;IL6;IL3RA;...
Hepatocellular carcinoma -1.83 8.29e-3 135/168 (80.36%) GAB1;TERT;DVL1;...
Antigen processing and presentation -1.87 6.14e-3 60/78 (76.92%) HLA-A;CANX;HLA-DOB;...
ABC transporters -1.91 1.73e-3 37/45 (82.22%) ABCA8;DEFB1;CFTR;...
Steroid hormone biosynthesis -1.99 0.00e+0 43/61 (70.49%) HSD17B3;CYP1A2;CYP3A5;...
Allograft rejection -2.00 0.00e+0 32/38 (84.21%) CD40LG;FASLG;HLA-DOA;...
Graft-versus-host disease -2.08 0.00e+0 32/42 (76.19%) FASLG;KIR3DL1;HLA-DOA;...
Retinol metabolism -2.08 0.00e+0 41/68 (60.29%) RDH5;CYP2W1;BCO1;...
Autoimmune thyroid disease -2.11 0.00e+0 46/53 (86.79%) CD40LG;FASLG;HLA-DOA;...
Metabolism of xenobiotics by cytochrome P450 -2.18 0.00e+0 49/77 (63.64%) GSTT2;CYP1A2;CYP2D6;...
Tyrosine metabolism -2.20 0.00e+0 30/36 (83.33%) TPO;AOX1;ADH1C;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 20uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 10uM 6H, 24H, 48H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 12uM - 100uM 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colon carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 TP53(-/-) CVCL_HD97 Homo sapiens 0.04uM - 10uM 24H
HCT 116 CVCL_0291 Homo sapiens 0.04uM - 10uM 24H
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 (Parent) CVCL_0291 Homo sapiens 0.04uM - 10uM 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 100uM 6H, 24H, 48H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 20uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.11uM - 20uM 6H, 24H, 48H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H